LLY DMA

As of date:	9/21/2023
LLY stock price:	550.13
LLY 50 DMA:	519.58
LLY 200 DMA:	413.26
LLY MACD (200-50):	-106.32

Also see:
LLY Market Cap History
LLY Shares Outstanding History
LLY YTD Return
LLY RSI
LLY MACD
LLY Technical Analysis

Predict charts, win cash @ chartsweeps.com

Zillow Group (ZG) Shares Cross Below 200 DMA
1 hour, 20 minutes ago

UNIT Crosses Below Key Moving Average Level
1 hour, 20 minutes ago

Zillow Group (Z) Shares Cross Below 200 DMA
1 hour, 20 minutes ago

Equinix (EQIX) Shares Cross Below 200 DMA
1 hour, 24 minutes ago

Notable Two Hundred Day Moving Average Cross - CACC
1 hour, 33 minutes ago

Landstar System (LSTR) Shares Cross Below 200 DMA
1 hour, 35 minutes ago

Sonic Automotive (SAH) Shares Cross Below 200 DMA
1 hour, 49 minutes ago

MAS Makes Notable Cross Below Critical Moving Average
1 hour, 56 minutes ago

FDVV Shares Cross Below 200 DMA
1 hour, 56 minutes ago

ARK Fintech Innovation (ARKF) Shares Cross Below 200 DMA
1 hour, 56 minutes ago

MCAN Mortgage (MKP.CA) Shares Cross Below 200 DMA
1 hour, 57 minutes ago

CYB.CA Crosses Below Key Moving Average Level
1 hour, 57 minutes ago

Shares of PPA Now Oversold
1 hour, 58 minutes ago

TDSC Getting Very Oversold
1 hour, 58 minutes ago

ICF Crowded With Sellers
1 hour, 58 minutes ago

More Technical Analysis News

LLY DMA

LLY MACD

Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products and other therapies. Co.'s diabetes products include: Basaglar®, a long-acting human insulin analog for the treatment of diabetes; and Trajenta®, for the treatment of type 2 diabetes. Co.'s oncology products include: Alimta®, for treatment of patients with non-squamous cell histology and no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

When researching a stock like Eli Lilly , many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from LLY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for LLY stock — the real life supply and demand for the stock over time — and examines that data in different ways. One of those ways is to calculate a Simpe Moving Average ("SMA") by looking back a certain number of days. One of the most popular "longer look-backs" is the LLY 200 day moving average ("LLY 200 DMA"), while one of the most popular "shorter look-backs" is the LLY 50 day moving average ("LLY 50 DMA"). A chart showing both of these popular moving averages is shown on this page for Eli Lilly .

10 Most Oversold S&P 500 Stocks

10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying

10 ETFs With Most Upside To Targets

The DividendRank Top 25

Warren Buffett Dividend Stocks

10 Cheap Dividend Stocks Under $10

10 Top DividendRank'ed Energy Stocks

The 10 Highest Yielding Preferred Stocks

The 15 Most Active S&P Call & Put Options

Quotes delayed 20 minutes

Free LLY Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

Video: Technical Analysis

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Eli Lilly (LLY) is categorized under the Healthcare sector; to help you further research DMA, below are some other companies in the same sector:

MCK DMA
MDT DMA
MMM DMA
MOH DMA
MRK DMA
MRNA DMA
OGN DMA
PFE DMA
PODD DMA
REGN DMA
More Healthcare companies »

LLY DMA | www.StockDMA.com | Copyright © 2019 - 2023, All Rights Reserved

Nothing in StockDMA.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.